Abstract: The invention relates to a device for measuring the dose delivered through a radiosensitive film under exposure to ionizing radiations, to a system comprising such device and to the use of such device. More particularly, the device comprises a reflection film; at least one light source; a radiosensitive film; and an optical sensor system comprising a 2-D array of one or more photoresistor units and/or semiconductor units. The present invention also relates to a system comprising the device previously described; a readout integrated circuit unit connected to the optical sensor system of the device; and a processing unit connected to the readout integrated circuit. The present invention also relates to the use of a device as previously described.

Abstract: A compound of formula (1) R1—Wm—Xn-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp—Zq—R2, wherein AA1 is Phe; AA2 is Trp; AA3 is selected from Met, Leu and lie; AA4 is selected from Lys, Arg and Gln; AA5 is Arg; AA6 is Lys; AA7 is selected from Arg, Lys and His; AA8 is selected from Val, Ile, Leu and Met; and AA9 is Pro. The compound is useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes, in particular for improving the barrier function of the skin, for energizing the skin and as an anti-aging agent.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

Abstract: The invention relates to a compound of formula (I) R1 — Wm—Xn— AA1— A A2— A A3— AA4— A A5— AA6—Yp—Zq—R2, a stereoisomer and/or cosmetically acceptable salt thereof wherein: AA1 is Arg, Lys or no amino acid; AA2 is Arg or Lys; AA3 is Gln, Glu, Asn or Asp; AA4 is Met or Leu; AA5 is Glu, Asp or Gin; AA6 is Glu, Asp, Gin or no amino acid; and AA1 is different from AA6. The compounds are useful for the treatment and/or prevention of the symptoms of skin aging and, in particular, for the treatment and/or prevention of skin wrinkles, the treatment and/or prevention of a sagging appearance of the skin, and/or the reduction and/or prevention of facial asymmetry.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: A compound of formula (I) R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2, a stereoisomer and/or cosmetically acceptable salt thereof, and a method of treatment using the compound are described. In the compound, AA1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA2 is Val, Ile, Leu or Ala; AA3 is Tyr, Phe, Trp, Lys, Arg or His; AA4 is Lys, Arg, His, Pro or Val; AA5 is Asn, Asp, Gln or no amino acid; AA6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment of the symptoms of skin aging and, in particular, for the treatment of skin wrinkles, the treatment of a sagging appearance of the skin, and/or the reduction of facial asymmetry.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: A peptide has the formula (I) R1—Wm—Xn-AA1-AA2-AA3-Yp—Zq—R2, where AA1 is Tyr or Trp, AA2 is Val, Ile, Leu or Met, AA3 is Tyr, Phe or Trp, W, X, Y and Z are amino acids, m, n, p and q are each 0 or 1, and m+n+p+q is less than or equal to 2. R1 is H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, aralkyl, or R5—CO—. R5 is H, a non-cyclic aliphatic group, alicyclyl, aryl, aralkyl, heterocyclyl or heteroarylalkyl. R2 is —NR3R4, —OR3, or —SR3. R3 and R4 are each H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, or aralkyl. R1 and R2 are not amino acids. Cosmetic or pharmaceutical compositions may include the peptide. It find use in reduction of lipid accumulation in the skin, treatment of cellulite, and treatment of symptoms of skin aging.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.

Abstract: Optical fiber based current measuring equipment for measuring the current circulating through a conductor. The equipment includes an interrogator having a light emitter and a light receiver, and a sensing portion close to the conductor, the interrogator and the sensing portion being connected through at least one standard single-mode intermediate fiber. The light emitter of the interrogator is configured to emit sets of at least two polarized light pulses to the sensing portion, the pulses being polarized with a specific degree difference, and the light receiver (4) is configured to determine the current circulating through the conductor depending on the pulses it receives in return from the sensing portion. A method for measuring the current circulating through a conductor with the use of an optical fiber based current measuring equipment is also provided.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: Optical fiber based current measuring equipment for measuring the current circulating through a conductor. The equipment includes an interrogator having a light emitter and a light receiver, and a sensing portion close to the conductor, the interrogator and the sensing portion being connected through at least one standard single-mode intermediate fiber. The light emitter of the interrogator is configured to emit sets of at least two polarized light pulses to the sensing portion, the pulses being polarized with a specific degree difference, and the light receiver (4) is configured to determine the current circulating through the conductor depending on the pulses it receives in return from the sensing portion. A method for measuring the current circulating through a conductor with the use of an optical fiber based current measuring equipment is also provided.

Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.